← Back
Passage BIO
PASG · listed on Nasdaq · worth $14.36 million
$3.35
−1.99% on Oct 30
No insider bought Passage BIO stock in the last year. They sold it 2 times, $113.2K in all.
Red dot = an insider sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
2.9M shares
90% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, two insiders sold Passage BIO stock and none bought. None of the 2 sales is marked on its filing as planned in advance; all by company executives. The biggest seller was William Chou, PRESIDENT AND CEO.
Big investors
People and funds that reported owning 5% or more of Passage BIO, newest first.
All reports
Every insider trade and SEC report we hold for Passage BIO.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Sep 15, 2025BoughtLynx1 Capital Management LPSep 15, 2025 · 10% owner+1.9%via a trust or family11,900 @ $6.99$83.2K
Sep 15, 2025BoughtLynx1 Capital Management LPSep 15, 2025 · Traded Sep 12, 2025 · 10% owner+3.2%via a trust or family19,783 @ $6.99$138.3K
Sep 15, 2025BoughtLynx1 Capital Management LPSep 15, 2025 · Traded Sep 11, 2025 · 10% owner+0.1%via a trust or family325 @ $6.96$2.3K
6 more with Pro →Analysts, earnings and news
Analysts' price target
$15.50 average
2 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
2 of 3 quarters above
Q4 '25−$4.09 a share−$1.29
Q3 '25−$2.44 a share+$0.53
Q2 '25−$2.96 a share+$1.19